Sodium Fluoride

A12C - Other mineral supplements ATC A12CD01 Small molecule approved 1972 Parenteral Topical

JFDA label: Zymafluor Tab

Mechanism of Action

Fluoride F18 ion accumulates in the skeleton with increased deposition in the vertebrae and pelvis to define areas of abnormal osteogenic activity.

Indications

Approved

Skeletal imaging

Contraindications

Source: Lexicomp

There are no contraindications listed in the manufacturer’s labeling Absolute

Dosing

Source: Lexicomp

Skeletal imaging: IV: 8 to 12 mCi (300 to 450 MBq)

Skeletal imaging: IV: Weight-based doses (0.06 mCi/kg [2.1 MBq/kg]) ranging from 0.5 to 4 mCi (19 to 148 MBq) were reported in clinical experience.

There are no dosage adjustments provided in the manufacturer's labeling.

Warnings & Precautions

Source: Lexicomp

Cancer

Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer. Special populations:

Pediatric

May localize in areas of bone turnover, including developing long bones. Children are more sensitive to radiation; therefore, the lowest radiation-absorbed dose should be utilized to minimize risk to the patient and provide quality imaging (Gelfand, 2011). Special handling:

Radiopharmaceutical

Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel (eg, wear waterproof gloves and use effective shielding). Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. Other warnings/precautions:

Absorbed radiation

Bone, bone marrow, and urinary bladder are target organs for high absorbed radiation doses. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.

Appropriate use

Imaging: Patients should void immediately before imaging the radioactivity in the lumbar spine or bony pelvis.

Pregnancy & Lactation

Pregnancy

FDA category C

Animal reproductive and developmental studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm. Women should be evaluated for pregnancy prior to administration.

Lactation

Avoid

Due to the potential for adverse reactions in the nursing infant, breast-feeding is not recommended. The manufacturer recommends interrupting breast-feeding for ≥24 hours to minimize radioactivity exposure and risk to the infant.

Chemistry & Properties

Formula	FNa
Molecular weight	41.99 g/mol
IUPAC name	sodium fluoride
CAS	7681-49-4
PubChem CID	5235
InChIKey	`PUZPDOWCWNUUKD-UHFFFAOYSA-M`

SMILES

[F-].[Na+]

Biology & Pharmacokinetics

Pharmacokinetics

Half-life	1.5 h

Registered Products (2)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
ZYMAFLUOR Tab	Tablet 0.25 mg	400 tab	Nabulsi Drug Store	2.640
Zymafluor Tab	Tablet 1 mg	250 tab	Nabulsi Drug Store	4.230